OLDSMAR, Fla., Aug. 6 /PRNewswire-FirstCall/ -- Cryo-Cell International, Inc. , one of the largest and most established leaders in stem cell innovation, will present data on the proliferative ability of stem cells found in menstrual blood (known as MenSCs) during the Fourth China Medical Biotech Forum, August 8-10 in Dalian, China. Data from an in vitro study show that MenSCs proliferate rapidly and have significant potential to develop into multiple cell types. Dr. Julie Allickson, Vice President of Laboratory Operations and Research and Development at Cryo-Cell, will present the data at the Forum as part of a keynote address.
“We are pleased to share these promising early study findings with the distinguished researchers attending the CMBF,” said Dr. Allickson. “MenSCs are sufficiently potent and could potentially be used in the future for a variety of therapies and conditions, and we look forward to gaining further insights from the current clinical trials testing the safety and efficacy of the cells in several different animal models.”
“Cryo-Cell’s keynote presentation at the China Medical Biotech Forum is a strategic opportunity that comes at an exciting time for global stem cell research and development,” stated Mercedes A. Walton, Cryo-Cell’s Chairman & CEO. “The Company continues to build a robust intellectual property portfolio based on Cryo-Cell’s menstrual stem cell technology. We are honored to share the Company’s research with preeminent scientists and physicians who are attending the China Medical Biotech Forum from around the world.”
About C’elle
The C’elle(SM) service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.
Forward-Looking Statement
SOURCE Cryo-Cell International, Inc.
CONTACT: General Media, Kristin Boza, +1-312-233-1295,
kristin.boza@edelman.com; or Financial Media, Dianne Will, Investor
Relations, Cryo-Cell International, Inc., +1-518-398-6222,
dwill@willstar.net
Web site: http://www.cryo-cell.com/
